Incyte Corporation INCY

Revenue Intelligence Report • 64 quarters of SEC filing data • Updated 2026-03-15

Revenue is driven more by SG&A spending than R&D, with elasticity estimates of 1.10% revenue per 1% SG&A increase and 0.45% per 1% R&D increase, indicating SG&A investments deliver the larger marginal lift. The model's holdout performance shows moderate predictive precision, predicting about 1.4B for the latest quarter versus 1.507B actual (8.8% error) and an overall MAPE of 16%. For Incyte, the latest quarterly revenue was about 1.51B and the full-year forecast calls for 5.6B, up roughly 9.8% year over year, suggesting continued top-line momentum. However, ROI interpretation relies on margins and costs not provided here; the growth outlook appears solid as SG&A continues to drive revenue while R&D remains secondary in elasticity, pending margin results.

Investment Thesis

At 16.0% MAPE, the model captures Incyte Corporation's broad revenue trajectory, though quarterly variability suggests sensitivity to external factors. R&D investment shows a 0.45x multiplier — each 1% increase in R&D spend is associated with a 0.45% revenue increase, signaling strong innovation-to-revenue conversion. Sales & marketing spend shows a 1.10x elasticity, suggesting effective go-to-market execution.

Next FY Revenue
$5.65B
+9.8% YoY
R&D Elasticity
0.45x
SG&A Elasticity
1.10x
Model Accuracy
16.0% MAPE
Holdout validation: The model predicted $1.4B vs the actual $1.5B — an error of 8.8%.

Revenue Forecast

INCY Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $1.4B $1.5B $0.9B – $2.1B +16.6% ✓ In range
Q2 2026 $1.4B $0.8B – $2.5B +30.7%
Q3 2026 $1.4B $0.7B – $2.9B +15.9%
Q4 2026 $1.4B $0.6B – $3.3B +4.3%
Q1 2027 $1.4B $0.6B – $3.7B -4.7%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Incyte Corporation's systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Sep–Nov) 0.9944 -0.6% In line with trend 15
FQ2 (Dec–Feb) 1.072 +7.2% +7.2% above trend 15
FQ3 (Mar–May) 0.9089 -9.1% -9.1% below trend 15
FQ4 (Jun–Aug) 0.9859 -1.4% In line with trend 15

How Spending Drives Revenue

INCY Spending Timing
Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. Model: ARDL (log-log) with 64 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

EW LLY DHR VRTX REGN GEHC COR IQV